

Product Focus

Pharmaceutical Distribution

Market disruption/supply issue

June 12, 2018

Important Pfizer prefilled syringe safety information

New special handling instructions due to potential for cracked needle hubs and particulate in multiple Carpuject™ Luer Lock Glass Syringe products

Hospira, a Pfizer company, issued the attached letter to alert healthcare providers of the potential of cracked needle hubs and particulate in the following Carpuject™ Luer Lock Glass Syringe Products:

Supplier name	CIN	Item description	NDC number
Pfizer Injectables	3537073	HEPARIN SOD5000U/0.5 50X0.5 PF	00409131632
Pfizer Injectables	3672433	HYDROMORPH 1MG 10X1 LL SLM C2	00409128331
Pfizer Injectables	3675915	HYDROMORPH2MG10X1 LL SLM PF C2	00409131230
Pfizer Injectables	2928802	LABETALOL HCL 5MG/ML 10X4ML LL	00409233934
Pfizer Injectables	3670551	LORAZEPAM 2MG 10X1ML LL SLM C4	00409198530
Pfizer Injectables	4728796	MORPHINE 2MGML10X1ML SLL PF C2	00409189001

Next steps

In order to minimize the potential risk of adverse events with these products, special handling directions described in the attached letter are required prior to administering the affected products to patients. To help alleviate the critical drug shortage of these products, Hospira has evaluated product lots in its control and, in coordination with the FDA, is releasing the impacted lots listed in Appendix 1.

Special handling instructions in this letter only apply to Carpuject™ lots described in Appendix 1. All other Carpuject™ lots may be administered following routine procedures. Please ensure any provider in your institution who may be involved in the administration of these products receives a copy of this letter and specifically reviews the special handling directions in the attached letter.

Pfizer has coordinated with the FDA and completed the following actions to ensure adequate communication, awareness and patient safety for the impacted products:

- Utilized Stericycle to distribute the attached Dear Healthcare Provider Letter (DHCP) to customers offering special handling instructions.
- The DHCP letter has been posted by the FDA in addition to both the pfizerinjectables.com and pfizerinjectablessupply.com websites.
- Pfizer's field sales team will be messaging the DHCP to customers within their territory.
- The topic has been discussed in detail with our shared customers who have joined recent Customer Webex sessions related to supply recovery.

Please contact Hospira Customer Service at 844.646.4398 (Mon.-Fri. 8 a.m.-7 p.m. EST) or your Hospira representative for any questions regarding this notification.

As a pharmaceutical distributor, Cardinal Health does not make clinical recommendations and is not in a position to recommend alternative products that meet your individual patient's health needs. As a licensed healthcare professional, you are solely responsible to determine when and if an alternative product is appropriate for the treatment of a patient. However, as a pharmaceutical distributor, we do want to help you understand and manage the supply demands on other products that may result from a supply disruption. In light of the current disruption in the supply of these products, we are monitoring customer demand and supply availability of the products above. We recommend that you monitor these products as well and determine whether any change in your purchasing patterns may result from the supply disruption described in this *Product Focus*.